Why Are Hematocrit Levels Different in Males and Females?

The gap between male and female hematocrit levels, the percentage of blood volume occupied by red blood cells, is driven primarily by sex hormones. Women have mean hemoglobin levels roughly 12% lower than men, a difference so consistent it appears across many species of mammals, birds, and reptiles.¹ Testosterone boosts red blood cell production through multiple pathways, estrogen actively restrains it, and menstrual iron loss further widens the divide. What looks like a simple number on a lab report reflects a complex interplay of hormones, iron metabolism, and blood volume regulation.

How Testosterone Pushes Hematocrit Up

Testosterone raises hematocrit through at least two distinct mechanisms that work in parallel. First, it stimulates erythropoietin (EPO), the hormone produced mainly by the kidneys that tells bone marrow to make more red blood cells. Research has shown that testosterone recalibrates the relationship between EPO and hemoglobin, essentially raising the “thermostat” at which the body decides it has enough red cells.² The result is that men’s bone marrow keeps producing red cells at hemoglobin levels where a woman’s marrow would throttle back.

Second, testosterone suppresses hepcidin, a liver hormone that acts as the master regulator of iron availability. When hepcidin is high, iron stays locked inside storage cells and can’t be used for making hemoglobin. When testosterone pushes hepcidin down, more iron flows into the bone marrow, fueling faster red blood cell production. In one study, testosterone administration over 12 months increased red blood cell count by about 9%, hematocrit by 4%, and hemoglobin by 8%, while slashing hepcidin by 57%.³ This hepcidin suppression happens quickly, within the first week of high-dose testosterone exposure, and the effect is dose-dependent.⁴

At a molecular level, testosterone’s receptor in liver cells physically interferes with the signaling proteins that normally turn on hepcidin production. Specifically, the androgen receptor grabs onto molecules called Smad1 and Smad4, pulling them away from the hepcidin gene’s “on switch.”⁵ So testosterone simultaneously tells the kidneys to demand more red cells and rearranges iron metabolism to supply the raw materials for building them.

How Estrogen Holds Hematocrit Down

It would be easy to frame the sex difference as purely testosterone-driven, but estrogen actively suppresses red blood cell production in its own right. Research on cells from patients with chronic mountain sickness, a condition of excessive red cell production at high altitude, showed that estrogen cut the number of early red cell colonies in half and reduced the proportion of mature red blood cells by roughly six-fold compared to untreated cells.⁶ Testosterone, by contrast, produced only a slight and statistically insignificant increase in colony production in the same experiments. This finding helps explain why chronic mountain sickness disproportionately affects men and postmenopausal women: estrogen appears to act as a brake on runaway red cell production.

The practical implication is that the sex difference in hematocrit isn’t just about men having more of a stimulant. Women have an active suppressor. Remove estrogen (as happens after menopause), and hematocrit tends to drift upward. Add it (as in hormone therapy for transgender women), and hematocrit drops. The gap between male and female blood counts is the product of two hormonal systems pulling in opposite directions simultaneously.

Menstrual Blood Loss and Iron Depletion

Hormones set the parameters, but monthly blood loss through menstruation compounds the difference on the iron side. Every menstrual cycle removes iron-rich red blood cells from the body. Over time, this creates lower iron stores in premenopausal women compared to men or postmenopausal women. A study of premenopausal blood donors found that menstrual blood loss was a major independent factor in determining both hemoglobin and ferritin (the body’s main iron storage marker), accounting for about 8% of the variance in hemoglobin levels. Women with heavy menstrual bleeding had more than three and a half times the odds of being anemic.⁷

The flip side of this is visible when menstruation stops. Women who were not menstruating (whether due to amenorrhea, contraceptive methods, or menopause) had lower rates of iron depletion than those with regular cycles. One study found that iron depletion was about 26% in women with regular ovulatory cycles compared to 15% in those who were not menstruating.⁸ The same blood donor study noted that women using a levonorgestrel-releasing intrauterine device, which dramatically reduces menstrual flow, had markedly lower odds of iron deficiency.⁷ Iron deficiency doesn’t just cause fatigue; it directly constrains how much hemoglobin the bone marrow can produce, even when the hormonal signals are telling it to make more.

Plasma Volume Adds Another Layer

Hematocrit is a ratio: red blood cells divided by total blood volume. That means it can shift not only because red cell mass changes but also because the liquid portion of blood (plasma volume) changes. Women tend to carry more plasma relative to their red cell mass, which dilutes the reading further. A recent study found that when blood volume was expressed relative to body mass, women’s values were about 25% lower than men’s. But when the comparison was adjusted for lean body mass instead, women actually had about 6% higher blood volume, driven by a larger plasma compartment.⁹

This matters because it means some of the apparent hematocrit gap is a dilution effect rather than a red cell deficit. Women carry relatively more plasma for their lean mass, which pushes their hematocrit percentage down independently of how many red blood cells they actually have. Animal data reinforces this: female rats have about 18% more plasma volume per unit body weight than male rats, contributing to a lower hematocrit even though the red cell difference itself is modest.¹⁰ Researchers studying athletes have found that even after matching men and women for aerobic fitness, females maintained 14% higher plasma volume relative to their lean mass and about 8% lower red cell volume and total hemoglobin mass, suggesting the body manages oxygen delivery differently by sex rather than simply having “less” of everything.¹¹

When the Gap Opens During Puberty

Boys and girls have essentially identical hematocrit levels throughout childhood. The divergence begins at puberty, tightly tracking the rise in testosterone in boys. A study that followed adolescents through pubertal stages found that hemoglobin concentration didn’t change during maturation in girls but rose about 11% in boys. Total hemoglobin mass, a measure of how much hemoglobin is circulating in the entire body, increased by roughly 95% in boys between early and late puberty, compared to about 33% in girls over the same developmental window.¹² That enormous gap in total hemoglobin mass reflects both the greater red cell production driven by testosterone and the larger body size boys are simultaneously developing.

The timing is informative: the gap doesn’t emerge until testosterone levels climb, which pins the hormonal mechanism more firmly than any cross-sectional comparison of adult men and women ever could. Before puberty, there’s no meaningful sex difference in hematocrit. After puberty, the gap remains stable throughout adult life until women reach menopause, when it narrows somewhat as estrogen declines and menstrual iron loss ceases.

Evidence from Gender-Affirming Hormone Therapy

Perhaps the most convincing demonstration that sex hormones are the primary driver comes from people undergoing gender-affirming hormone therapy. When transgender men begin testosterone, their hematocrit rises. When transgender women begin estrogen (and testosterone suppression), their hematocrit falls. In both cases, the blood counts migrate toward the values typical of the affirmed gender.

A large longitudinal study found that transgender men on testosterone experienced erythrocytosis (hematocrit above the upper limit) at seven times the rate of cisgender men and 83 times the rate of cisgender women.¹³ That dramatically elevated rate compared to cisgender men likely reflects the fact that exogenous testosterone can produce more volatile peaks in hormone levels than the body’s own steady production. Meanwhile, transgender women on estrogen and anti-androgens saw their hemoglobin and hematocrit trend downward, and they developed anemia at about six times the rate of cisgender men.¹³ A separate cohort study confirmed the same pattern: red cell count, hemoglobin, and hematocrit all decreased significantly in transgender women and increased significantly in transgender men.¹⁴

This “natural experiment” makes a strong case that the sex difference in hematocrit is overwhelmingly hormonal. Swap the dominant hormone, and the blood counts follow within months.

Testosterone Therapy and Erythrocytosis Risk

The same testosterone-driven red cell boost that creates normal male hematocrit levels becomes a clinical concern when testosterone is given as a medication. Testosterone replacement therapy for men with low levels predictably pushes hematocrit up, and all formulations do so: gels, patches, oral preparations, and injectable forms. A systematic review and meta-analysis of randomized trials found that every form of testosterone therapy produced significant hematocrit increases compared to placebo, ranging from about 1.4 percentage points for patches up to about 4.3 points for oral testosterone undecanoate.¹⁵

Whether this increase poses real cardiovascular danger is debated. A large retrospective study using data from about 74 million patients found that men who developed erythrocytosis (hematocrit at or above 52%) while on testosterone therapy had modestly higher odds of major cardiovascular events and blood clots compared to those who did not, with an odds ratio of about 1.35.¹⁶ This is real but not enormous, and it remains uncertain whether the elevated hematocrit itself is the cause or simply a marker for higher testosterone exposure. Guidelines generally recommend monitoring hematocrit during testosterone therapy and considering dose adjustment if it climbs too high, though the evidence behind the specific cutoffs is thinner than many clinicians realize.

Altitude, and Why the Gap Persists Up the Mountain

Living at high altitude forces the body to produce more red blood cells to compensate for lower oxygen availability. Both men and women see their hematocrit rise at altitude, but the sex gap persists. A study across different regions of Saudi Arabia at varying elevations found that both men and women had higher hemoglobin at higher altitudes, but the male-female difference remained at every elevation. The researchers suggested a correction factor of about 0.3 g/dL of hemoglobin for every 1,000 meters of altitude for both sexes.

The persistence of the gap at altitude reinforces that it is fundamentally hormonal, not simply a response to environmental oxygen levels. If the difference were mainly about oxygen delivery needs, you might expect altitude-driven increases to eventually close the gap, but they don’t. Men and women both shift their hematocrit upward in parallel, maintaining the offset set by their respective hormonal environments. In fact, the condition of chronic mountain sickness, in which hematocrit climbs to dangerously high levels, predominantly affects men and postmenopausal women, which circles back to estrogen’s protective suppression of excessive red cell production.⁶

The Viscosity Trade-Off and Cardiovascular Differences

There is an optimal range for hematocrit, a sweet spot where the blood carries enough red cells for good oxygen delivery but remains fluid enough to flow easily through small vessels. Theory and observation align on this: across humans and many other species, hematocrit in the systemic circulation tends to settle somewhere around 30 to 50%. Too few red cells and oxygen delivery suffers. Too many and blood becomes thick, sluggish, and harder for the heart to pump.

Women’s lower hematocrit may confer a real vascular advantage. Research in elderly populations has found that women have lower blood viscosity than age-matched men, and this is associated with better endothelial function, the ability of blood vessel walls to relax and dilate properly. The authors of one study concluded that women’s lower viscosity and better vascular function may help explain why they develop cardiovascular disease later and less frequently than men of the same age.¹⁷ The lower hematocrit that looks like a “deficit” on a lab report might actually be part of the reason women’s cardiovascular systems age more gracefully.

Why Drug Dosing Can Depend on Hematocrit

A less obvious consequence of the sex difference in hematocrit is that it can affect how drugs distribute in the blood. Many medications partition differently between plasma and whole blood because red blood cells take up some portion of the drug. When hematocrit is higher, there’s proportionally less plasma per unit of blood, and the ratio between drug concentration in plasma versus whole blood shifts. Research on benzodiazepines found a strong positive correlation between hematocrit and the plasma-to-blood concentration ratio, with the relationship differing significantly between sexes because of their different average hematocrit values. This means a drug level measured in plasma can correspond to different whole-blood concentrations depending on the patient’s hematocrit, which in turn varies predictably by sex. For most medications this difference is small enough to be clinically irrelevant, but for drugs with narrow therapeutic windows, it can matter.

The Cross-Species Pattern

The sex difference in hematocrit isn’t unique to humans. It appears across a wide range of mammals, birds, and reptiles, which suggests it is deeply embedded in vertebrate physiology rather than a quirk of human biology.¹ Studies of mammals at moderate altitudes (around 1,500 to 2,100 meters) have found that the hematocrit response to altitude varies among different mammalian groups and between sexes within those groups, but the underlying male-female difference remains a recurring feature. In some primates, the male-specific increase at altitude was the more prominent change, while in carnivores, females showed a more pronounced altitude response.¹⁰ The broad cross-species consistency of the sex gap points to strong evolutionary conservation: whatever advantage this hormonal arrangement provides, it has been maintained across hundreds of millions of years of vertebrate evolution.

One plausible explanation is that the higher hematocrit in males supports the greater oxygen demands of larger muscle mass and more intense physical activity patterns seen in many species with sexual dimorphism. Meanwhile, the lower hematocrit in females may represent an optimization for pregnancy, during which plasma volume expands dramatically and blood viscosity needs to stay low to support placental circulation. Neither sex has a “wrong” hematocrit; both are tuned to the physiological demands that have shaped them over evolutionary time.